Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | VCP | P55072 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 3/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22520618 | 0.90 | NPC1 (0.56) | NPC1VCPHRH3DAO | |
| SCHEMBL18389833 | 0.89 | NPC1 (0.58) | NPC1VCPHRH3DAOMAOB | |
| SCHEMBL27013338 | 0.84 | NPC1 (0.50) | NPC1VCPHRH3DAOCARM1 | |
| SCHEMBL26949131 | 0.84 | NPC1 (0.53) | NPC1VCPHRH3 | |
| SCHEMBL24475383 | 0.81 | NPC1 (0.44) | NPC1VCPHRH3MAOB | |
| SCHEMBL26949128 | 0.79 | NPC1 (0.47) | NPC1VCPHRH3CARM1PRMT6 | |
| SCHEMBL20965546 | 0.79 | NPC1 (0.55) | NPC1VCPCARM1PRMT6 | |
| SCHEMBL24233184 | 0.78 | NPC1 (0.46) | NPC1VCPHRH3CARM1PRMT6 | |
| SCHEMBL13741291 | 0.78 | HRH3 (0.51) | NPC1VCPHRH3CARM1 | |
| SCHEMBL25122525 | 0.77 | NPC1 (0.45) | NPC1VCPHRH3CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA UK LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ESR1, GPER1, ESRRG | NPC1 4258/4885VCP 659/4885HRH3 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.